The current set of trials are/were designed through CDA's for the sole reason of expressing the potential on the indications. That is why they're small short trials. Big pharma wants to see an expression of the goods before potentially front loading the financing. Yes, I believe we all know the alternatives. If IPIX is successful, which thus far they seem to be very well on the right track, I very much doubt a partnership will be a problem. Investors would need to have a bit of patience and ignore the day trading trolls that'll undoubtedly be crying every day until full results are published. Top line data could bring on a partnership right away, but I think they would wait for full data. A partnership based on what the company will be presenting would EASILY cover all the cost, along with milestone payments for the indication. And then some.

See how it goes. Click that easy button.